Clinical trial
RNA-Loaded Dendritic Cell Cancer Vaccine
NCT00087984 · Argos Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00087984 |
|---|---|
| Title | RNA-Loaded Dendritic Cell Cancer Vaccine |
| Official title | A Phase I/II Study To Examine The Safety, Feasibility, Immunological Response, And Measures Of Clinical Antitumor Activity After Administering Unselected, Autologous, Amplified Tumor Total RNA-Transfected, Dendritic Cell Vaccine (MB-002) To Patients With Metastatic Renal Cell Carcinoma |
| Lead sponsor | Argos Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Biological |
| Interventions | MB-002 |
| Enrollment | 26 |
| Start date | Jan 1, 2004 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Jul 20, 2004 |
| Last update posted | Feb 18, 2013 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: